Clinical Trial

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essential Thrombocythemia
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-07-28; most recent amendment 2025-08-08.
Status change: Recruiting → Active, Not Recruiting 2024-10-21
Status change: Not Yet Recruiting → Recruiting 2022-11-09
Trial Details
NCT Number NCT05482971
Lead Sponsor PharmaEssentia
Conditions Essential Thrombocythemia
Enrollment 91 participants
Start Date 2022-09-29
Primary Completion 2025-05-09 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-13